Announcement on Convening the Q3 2025 Performance Briefing
Filed with SSE · · 2 pages · Chinese
Beijing Hotgen Biotech Co. Ltd. on 6ix
Earlier from Beijing Hotgen Biotech
- Announcement on Result of Shareholding Reduction by Controlling Shareholder
- Announcement on Resolutions of the 4th Extraordinary General Meeting in 2025
- Announcement on Proposal of Canceling the 4th Extraordinary General Meeting in 2025
- Announcement on Increasing the Estimated Amount for Daily Related Party Transactions in 2025
- Announcement on Voluntary Disclosure of Positive Preliminary Results of the Phase Ib Clinical Study of the Innovative Drug SGC001 of the Joint-stock Company
Later from Beijing Hotgen Biotech
- Announcement on Voluntary Disclosure of Progress in the Share Repurchase through Call Auction
- Voluntary Disclosure Announcement on Designation as a National-Level "Little Giant" Enterprise (Specialized, Sophisticated, Distinctive, and Innovative)
- Announcement on Joint Investment in Yaojing Gene with a Related Party and Related Party Transaction
- Announcement on Voluntary Disclosure of Recent Qualifications Obtained by the Joint-stock Company of the Company
- Announcement on Resolutions of the 5th Extraordinary General Meeting in 2025
Follow Beijing Hotgen Biotech into a list and get an email when it puts out news.
Follow Beijing Hotgen Biotech